- This event has passed.
QB3 Seminar: Martin Babler, CEO, Principia Biopharma
December 9, 2020 @ 2:00 pm - 3:00 pm
QB3 SEMINAR: MARTIN BABLER, FORMER CEO, PRINCIPIA BIOPHARMA. “BUILDING A BEST-IN-CLASS PLATFORM FOR IMMUNE-MEDIATED DISEASE”
Sanofi recently acquired Principia Biopharma for $3.7 billion. Principia, founded in 2008, built a portfolio of drugs to treat immune-mediated conditions including multiple sclerosis, pemphigus and immune thrombocytopenia purpura, all currently in Phase 3 trials. The portfolio was developed using Principia’s Tailored Covalency® platform. Martin Babler, formerly Principia’s CEO, joined the company when it started operations in 2011 and led it through several rounds of financing, the IPO and the acquisition. In this candid talk, Martin will relate hard-won lessons from his experience as CEO.
WHERE & WHEN
Wednesday, December 9, 2:00 to 3:00 PM